Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IGCAR
- Development stage
- Preclinical
- Lead developer
- Ingenium Therapeutics
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Gene Therapies, Nanoparticles → Drug Delivery Systems, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
IGCAR is a preclinical-stage, 5th generation in vivo chimeric antigen receptor natural killer (CAR-NK) cell therapy being developed by Ingenium Therapeutics. Unlike traditional ex vivo CAR therapies that require complex laboratory modification of extracted cells, IGCAR utilizes a proprietary Polyplex mRNA delivery system to deliver CAR-encoding mRNA directly into the patient's endogenous natural killer cells. This approach aims to induce CAR expression in vivo, potentially simplifying the manufacturing process and increasing accessibility. The therapy is currently being investigated for the treatment of various solid tumors, although the specific CAR target has not been publicly disclosed.
- Other names
- in vivo CAR-NK
02
Targets
TF antigen (Thomsen-Friedenreich antigen)
Beyond the preview
Go deeper on IGCAR.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IGCAR.